Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

Dragana Milojkovic, MBBS, PhD, Richard E. Clark, Jennifer L Byrne, Brian J.P Huntly, Manoj Raghavan, Farooq A Wandroo, Sahra Ali, Belinda Austen, Jacqueline Ryan, Karsten Friedrich, Nicholas C.P. Cross, PhD, Adam J Mead, MD PhD

Blood (2017) 130 (Supplement 1): 2892.

https://doi.org/10.1182/blood.V130.Suppl_1.2892.2892

Published: 2017

Journal Articles

Increased Frequency of Constitutional Pathogenic ATM Mutations in CLL Patients Compared to Control Individuals Suggests An Aetiological Role.

Tatjana Stankovic, MD.PhD, Belinda Austen, Guy Pratt, Anna Skowronska, David Oscier, Martin JS Dyer, Estella Matutes, MD, PhD, Malcolm Taylor, Paul Moss, MBBS, PhD, FRCP

Blood (2009) 114 (22): 1250.

https://doi.org/10.1182/blood.V114.22.1250.1250

Published: 2009

Journal Articles

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

Chris Pepper, Thet Thet Lin, Guy Pratt, Saman Hewamana, Paul Brennan, Louise Hiller, Robert Hills, Rachel Ward, Jane Starczynski, Belinda Austen, Laura Hooper, Tatjana Stankovic, Chris Fegan

Blood (2008) 112 (9): 3807–3817.

https://doi.org/10.1182/blood-2008-05-157131

Published: 2008

Includes: Supplemental data

Journal Articles

A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL.

Giles Best, PhD, Anne Gardiner, BSc, Rachel Ibbotson, PhD, Aneela Majid, PhD, Renata Walewska, MD, Belinda Austen, MD, Tanja Stankovic, PhD, Martin Dyer, MD, David Graham Oscier, MD

Blood (2006) 108 (11): 2795.

https://doi.org/10.1182/blood.V108.11.2795.2795

Published: 2006

Journal Articles

Stratification by DNA Damage-Induced Apoptotic and Transcriptional Responses Provides Insight into the Molecular Mechanisms Underlying Blast Clearance Rates in Paediatric B-Precursor ALL.

Eliot Marston, MRes, Victoria Weston, PhD, Belinda Austen, BMBCH, Michael Wakelam, PhD, Sarah Lawson, BMBCH, Phil Darbyshire, BMBCH, Jenny Jesson, BSc, Paul Moss, BMBCH, Tatjana Stankovic, PhD

Blood (2006) 108 (11): 705.

https://doi.org/10.1182/blood.V108.11.705.705

Published: 2006

Journal Articles

Chronic Lymphocytic Leukaemia Has a More Aggressive Phenotype in Asians Compared to Caucasians.

Belinda Austen, Chaminda Gunawardana, Guy Pratt, Farooq Wandroo, Abe Jacobs, Judith Powell, Paul Moss

Blood (2006) 108 (11): 4965.

https://doi.org/10.1182/blood.V108.11.4965.4965

Published: 2006

Journal Articles

The Novel PARP Inhibitor, AZD2281, Targets Apoptotic Resistant ATM Mutant CLL Tumours for Cellular Killing.

Victoria Weston, PhD, Claire Baker, BSc, Belinda Austen, BMBCh, Malcolm Taylor, PhD, Paul Moss, PhD, Tanja Stankovic, PhD

Blood (2006) 108 (11): 2110.

https://doi.org/10.1182/blood.V108.11.2110.2110

Published: 2006

Journal Articles

CLL Tumours with a Deletion of 11q Form Two Functional Subgroups Based on the Mutation Status of the Remaining ATM Allele.

Belinda Austen, Maria Podinovskaia, Claire Almond, Graham Fews, Anne Gardiner, David Oscier, Paul Moss, Tanja Stankovic

Blood (2005) 106 (11): 710.

https://doi.org/10.1182/blood.V106.11.710.710

Published: 2005

Journal Articles

Identification of ATM Mutations in Multiple Myeloma Tumours.

Belinda Austen, BMBCH, Maria Podinovskaia, BSc, Jane Starcynski, PhD, Giancarlo Barone, BSc, Anne Reiman, BM, Phil Byrd, PhD, Guy Pratt, PhD, Malcolm Taylor, PhD, Tanja Stankovic, PhD

Blood (2005) 106 (11): 1562.

https://doi.org/10.1182/blood.V106.11.1562.1562

Published: 2005

Journal Articles

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL

Belinda Austen, Judith E. Powell, Azra Alvi, Ian Edwards, Laura Hooper, Jane Starczynski, A. Malcolm R. Taylor, Christopher Fegan, Paul Moss, Tatjana Stankovic

Blood (2005) 106 (9): 3175–3182.

https://doi.org/10.1182/blood-2004-11-4516

Published: 2005

Journal Articles

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival

Azra J. Alvi, Belinda Austen, Victoria J. Weston, Christopher Fegan, David MacCallum, Athos Gianella-Borradori, David P. Lane, Mike Hubank, Judith E. Powell, Wenbin Wei, A. Malcolm R. Taylor, Paul A. H. Moss, Tatjana Stankovic

Blood (2005) 105 (11): 4484–4491.

https://doi.org/10.1182/blood-2004-07-2713

Published: 2005

Journal Articles

ATM Mutations Define a Subset of B-CLL Tumours That Only Partially Correlates with 11q Status and Is Associated with Impaired Patient Survival.

Belinda Austen, MRCP, Christopher Fegan, MD, MRCP, MRCPath, Paul Moss, Phd,MRCP,MRCPath, Tanja Stankovic, Phd

Blood (2004) 104 (11): 774.

https://doi.org/10.1182/blood.V104.11.774.774

Published: 2004

Journal Articles

Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-κB survival pathway signaling

Victoria J. Weston, Belinda Austen, Wenbin Wei, Eliot Marston, Azra Alvi, Sarah Lawson, Philip J. Darbyshire, Mike Griffiths, Frank Hill, Jill R. Mann, Paul A. H. Moss, A. Malcolm R. Taylor, Tatjana Stankovic

Blood (2004) 104 (5): 1465–1473.

https://doi.org/10.1182/blood-2003-11-4039

Published: 2004

Journal Articles

Microarray analysis reveals that TP53 - and ATM -mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses

Tatjana Stankovic, Mike Hubank, Debbie Cronin, Grant S. Stewart, Danielle Fletcher, Colin R. Bignell, Azra J. Alvi, Belinda Austen, Victoria J. Weston, Christopher Fegan, Philip J. Byrd, Paul A. H. Moss, A. Malcolm R. Taylor

Blood (2004) 103 (1): 291–300.

https://doi.org/10.1182/blood-2003-04-1161

Published: 2004

NARROW

The Target UK Study: Real-World Evidence of Molecular Response to Tyrosine Kinase Inhibitors Supports European Leukemianet 2013 Recommendations for the Management of Chronic Myeloid Leukaemia

Increased Frequency of Constitutional Pathogenic ATM Mutations in CLL Patients Compared to Control Individuals Suggests An Aetiological Role.

Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers

A Novel Functional Assay Using Etoposide Plus Nutlin 3, FISH and Mutational Analysis Detects Heterogeneity of ATM/p53 Pathway Alterations in CLL.

Stratification by DNA Damage-Induced Apoptotic and Transcriptional Responses Provides Insight into the Molecular Mechanisms Underlying Blast Clearance Rates in Paediatric B-Precursor ALL.

Chronic Lymphocytic Leukaemia Has a More Aggressive Phenotype in Asians Compared to Caucasians.

The Novel PARP Inhibitor, AZD2281, Targets Apoptotic Resistant ATM Mutant CLL Tumours for Cellular Killing.

CLL Tumours with a Deletion of 11q Form Two Functional Subgroups Based on the Mutation Status of the Remaining ATM Allele.

Identification of ATM Mutations in Multiple Myeloma Tumours.

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL

A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival

ATM Mutations Define a Subset of B-CLL Tumours That Only Partially Correlates with 11q Status and Is Associated with Impaired Patient Survival.

Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-κB survival pathway signaling

Microarray analysis reveals that TP53 - and ATM -mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only